Don’t Let Your Tracker Get Stale: An Interview with Lucy Robin
Don’t Let Your Tracker Get Stale: An Interview with Lucy Robin By The Fulcrum Research Division Lucy Robin is one
Blog
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine
What Works, What Kills What, and Why It Matters By Mike Rea In pharmaceutical R&D, where billions ride on the
Minimizing Bias in Market Research: An Interview with Erik Coats
Minimizing Bias in Market Research: An Interview with Erik Coats By The Fulcrum Research Division Erik Coats is one of
Challenges and Concerns Raised by EFPIA on Joint Clinical Assessments
In the healthcare regulation sphere, proposed EU-level joint clinical assessments (JCAs) have sparked debate in the pharmaceutical industry. A recent EFPIA report highlights concerns about the rigidity of the guidelines, particularly in oncology, and suggests revisions to ensure a more efficient and adaptable evaluation process that accommodates diverse stakeholder needs across Europe.
Joint Clinical Assessment (EU HTA) Explained
A Comprehensive Exploration of Competitive Intelligence, Knowledge-Sharing, and Strategic Optimization in the Evolving Landscape of EU Health Technology Assessments. The
Rare Disease Day: Uniting Compassion, Data, and Global Action for Accessible Healthcare
What rare disease day means for our work at SAI Every leap year, on the 29th of February, the world
SAI MedPartners Expands Strategic Investments: Driving Growth and Elevating Consultancy Excellence
In the dynamic world of pharmaceutical services, strategic investments play a vital role in shaping the future of organizations. We are happy to announce that we have recently made headlines with our strategic acquisitions of Fulcrum Research Group (FRG) and Pharmaforce International (PFI). To shed light on the motivations behind these investments and the vision driving SAI MedPartners forward, we had the privilege of sitting down with the company’s CEO, Erik Nordhoy.
The Evolving World of Social & Digital Media Intelligence
It is no secret that social media is an essential channel for expressing opinions and sharing facts. Depicted through visual representations and the written word, the world works fundamentally through online channels, without which we would be thrown back into a rudimentary and non-progressive lifestyle.
Challenges in Hemoglobinopathies Projects and the Support of KOL Match
There are over 7,000 rare diseases described, affecting about 20-30 million people in the U.S. alone, according to the NIH. While each condition has its specificities, there are common challenges in the rare disease space, such as finding patients and leveraging centers of excellence and referral networks. This article discusses such challenges and how partnering with SAI’s subject matter experts can help overcome them.